Qualigen Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases. Its pipeline includes lead candidate QN-302, an investigational small molecule G-quadruplex-selective transcription inhibitor in Phase 1 clinical trials for pancreatic cancer and other solid tumors. The company is also advancing Pan-RAS in preclinical stages for advanced solid tumors, along with other programs such as QN-247, an oligonucleotide-based drug for nucleolin-expressing cancers; QN-165 for broad-spectrum infectious diseases; RAS-F, a small-molecule inhibitor targeting RAS mutations; and STARS, a selective target antigen removal system to eliminate circulating tumor cells, viruses, and immune checkpoints. Additionally, it offers FastPack, a rapid onsite immunoassay testing system leveraging proprietary nanoparticle technology. Qualigen Therapeutics Inc. targets unmet needs in oncology and infectious disease markets, aiming to deliver innovative treatments through advanced drug candidates and diagnostic tools. Founded in 1996 and headquartered in Carlsbad, California, the company operates in the competitive biopharmaceutical sector with a focus on clinical development and commercialization.